[Newsmp] AbbVie is showing off its presence in the autoimmune disease market.While Rinvoq and Skyrizi are expanding sales with fierce momentum, Humira is maintaining its growth despite the offensive of biosimilars.According to quarterly reports of major global Big Pharma, Humira posted sales of abou

[Newsmp] Korean pharmaceuticals are struggling even in the new year.As the slump continued in February, the market capitalization of 47 components (excluding preferred stocks) of the KOSPI pharmaceutical index shrank by nearly KRW 6 trillion.According to the Korea Exchange, stock prices of 40 out of

[Newsmp] Two items of eye drops containing rebamipide will be listed on the benefits list next month.Telmican-Q and Rozetelpine, four-drug combination treatments for hypertension and dyslipidemia, will expand their lineup, and the owner of the anticancer drug Taxol will transfer.Among the existing p

[NEWSMP] Benefit standards for Rebamipide 0.1g/5ml, Samil Pharmaceutical’s Reva-K Eye Drops and Kukjepharm's Reba-eye Eye Drops 2%, will be newly established.AbbVie’s interleukin-23 inhibitor Skyrizi (ingredient: risankizumab) is expected to expand its insurance benefits to psoriatic arthritis.Oral

[Newsmp] While half of the pharmaceutical firms whose closing accounts are in November and December disclosed their 2022 performance, more than two-thirds reported double-digit sales growth.According to 35 pharmaceutical companies that announced their earnings (preliminary) by the 13th, 24 companies

[Newsmp] While the Seoul Central District Court ruling involving Medytox and Daewoong Pharmaceutical came out, Evolus, the global distributor of Daewoong’s Nabota, officially announced that the civil judgment of the Seoul Central District Court does not affect the production, export, or overseas sal

[Newsmp] Semaglutide-containing products dominate diabetes and weight loss treatment market.Semaglutide injection Ozempic (Novo Nordisk), once a week administration, achieved KRW 10.8 trillion in annual sales last year, beating Trulicity (Eli Lilly) and leading the injection diabetes treatment marke

[Newsmp] A conference was held to highlight the clinical value of Korea’s first XPO1 inhibitor, Xpovio (ingredient: Selinexor).Antengene Korea (general manager Kim Min-Young) invited Professor Ajai Chari at Mount Sinai Hospital to hold a media session at GLAD Gangnam COEX Center in Seoul and present

[Newsmp] In the first month of 2023, the weakness in the pharmaceutical index continued.According to the Korea Exchange, the KOSPI pharmaceutical index fell 340.28p or 2.47% from 13,793.83 at the end of December to 13,453,55 at the end of January.The stock prices of 28 stocks, more than half of the

[Newsmp] The upper limit of health insurance benefits for Novartis’ Lucentis and AbbVie’s Venclexta will be drastically reduced from the 1st of next month.For Pfizer’s Vfend Tab. and Young Poong Pharmaceutical’s Clomiphen Citrate Tab. Youngpoong, the upper limits are expected to be increased, while

[Newsmp] Dupixent, a biologic medication that was approved for insurance benefits only for adults with atopic dermatitis, was also recognized for its reasonableness in children and adolescents.The Health Insurance Review and Assessment Service (HIRA) held the first Drug Benefit Evaluation Committee

[Newsmp]Cancer has no borders. So do we.In the bio and health industry, which is considered the largest market in the 21st century, there is a company focusing on relatively small markets rather than big markets such as the United States and Europe.BeiGene was launched in 2010 based on the philosoph

[Newsmp] Last year, the number of the Korean version of Orange Book registrations at the Ministry of Food and Drug Safety remained at the lowest level in the past 10 years.According to the Ministry of Food and Drug Safety’s information platform (https://nedrug.mfds.go.kr/), only 556 cases were liste

[Newsmp] Unlike the KOSPI pharmaceuticals index outperformed the KOSPI index last year, the KOSDAQ pharmaceuticals index performed slightly worse than the KOSDAQ index.KOSDAQ index fell 34.30% last year, and the KOSDAQ pharmaceuticals index declined 38.86%, a bit larger drop, according to the Korea

[Newsmp] Last year, the number of patents registered in the Ministry of Food and Drug Safety (MFDS) reached its highest level since 2014.According to the MFDS information platform (https://nedrug.mfds.go.kr/), a total of 278 patents were registered in 2022, up 123 cases from the previous year.It is

[Newsmp] The price index of cold medicines jumped more than 10% last year. Anti-inflammatory drugs also rose by over 7%.According to Statistics Korea, the price index for cold medicines stood at 113.50 in December, up 13.2% from a year earlier (based on 100 in 2020).Cold medicine’s price index was 1

[Newsmp] While a sharp wind hit the stock market in 2022, pharmaceutical stocks were also unable to escape the cold wave.There were only five pharmaceutical stocks in the top 100 in stock price growth on the KOSPI market, and only three of them recorded double-digit growth.Stock prices of 51 out of

[Newsmp] Migraine treatment Ajovy (Teva-Handok), Lucen-BS (Chong Kun Dang Pharmaceutical), a biosimilar referencing Ranibizumab (original product: Lucentis) and Ameliebou (Samsung Bioepis) will enter the pharmaceutical benefit list for the new year.Three products of Chong Kun Dang Pharmaceutical’s N

[Newsmp] The benefit standards for Teva-Handok’s migraine treatment Ajovy (ingredient: fremanezumab) and Viatris’ extensively drug-resistant tuberculosis treatment Dovprela (ingredient: pretomanid) will be newly established.Among the existing listed drugs, the PCSK9 inhibitor Praluent (ingredient: a

[Newsmp]Innovation that changes patients’ livesPfizer Korea presented a blueprint to create a healthier world through innovation after completing the relocation of its company building.Pfizer Korea, which recently moved the company to Namsan State Tower after wrapping up its 15-year Pfizer Tower era